WVE: Wave Life Sciences Ltd. Stock

by  •  • Comments Off on WVE: Wave Life Sciences Ltd. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,596.25
Enterprise Value ($M) 1,302.05
Book Value ($M) 217.39
Book Value / Share 1.42
Price / Book 7.34
NCAV ($M) 185.58
NCAV / Share 1.21
Price / NCAV 8.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.40
Return on Assets (ROA) -0.35
Return on Equity (ROE) -2.04

Liquidity (mrq)
Quick Ratio 2.89
Current Ratio 2.89

Balance Sheet (mrq) ($M)
Current Assets 320.39
Assets 352.21
Liabilities 134.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 108.30
Operating Income -110.40
Net Income -97.01
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -151.03
Cash from Investing -0.94
Cash from Financing 253.89

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Maverick Capital Ltd 5.40 -2.21
02-05 13G/A BlackRock, Inc. 6.10 28.25
11-12 13G/A Adage Capital Management, L.P. 6.66
11-12 13G/A M28 Capital Management LP 4.20 -16.39
11-12 13G/A Glaxosmithkline Plc 11.20 19.97
10-01 13D/A Ra Capital Management, L.p. 16.00 47.16
2024-02-14 13G/A 683 Capital Management, LLC 4.70 -6.67
2024-02-13 13G/A Bb Biotech Ag 3.70 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-12 235,304 1,263,077 18.63
2025-03-11 390,802 1,368,502 28.56
2025-03-10 214,812 1,235,032 17.39
2025-03-07 291,105 1,599,686 18.20

(click for more detail)

Similar Companies
VERA – Vera Therapeutics, Inc. VNDA – Vanda Pharmaceuticals Inc.
VRCA – Verrica Pharmaceuticals Inc. XENE – Xenon Pharmaceuticals Inc.
XNCR – Xencor, Inc.


Financial data and stock pages provided by
Fintel.io